Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $150 from $151 and keeps an Overweight rating on the shares. The firm updated its model to reflect expected Q4 IPR&D expense and revised dom/zim sales assumptions following the recent negative gastric cancer update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- AbbVie (ABBV) Commits $100B in U.S. Investment, Inks Deal with Trump to Avoid Tariffs
- Largest borrow rate increases among liquid names
- Argenx appoints Sandrine Piret-Gerard chief commercialization officer
- Halliburton, Schlumberger, SoFi, Procter, Gilead Trending
- Gilead price target raised to $154 from $144 at BofA